Aisling Capital LLC
Aisling Capital LLC is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Aisling Capital LLC.
Aisling Capital LLC is a company.
Key people at Aisling Capital LLC.
Key people at Aisling Capital LLC.
Aisling Capital LLC is a New York-based venture capital and private equity firm specializing in healthcare and life sciences investments, employing a multi-strategy approach across private and public companies, equity, debt, and structured securities.[1][2][3] Its mission centers on mid-market and growth-stage opportunities in biotech, as evidenced by a concentrated portfolio including top holdings like BridgeBio Pharma (72.85%), Verona Pharma (16.18%), and Syndax Pharmaceuticals (3.43%), with a $360 million market value as of mid-2025.[2] The firm impacts the startup ecosystem through targeted funding, such as raising $280 million for a biotech VC fund (closing $120 million short of target), supporting innovative life sciences companies from early to public stages.[3]
Founded in 2000, Aisling Capital began as a life sciences-focused investor and has evolved into a multi-strategy private equity firm emphasizing growth-stage biotech opportunities.[1][3] Key partners include Managing Partner Dr. Andrew Schiff, Partner Dr. Eric Aguiar, Chief Financial Officer and Chief Compliance Officer Robert Wenzel, and Controller Hannah Wieder, all based in New York.[3] The firm's trajectory includes managing five closed funds, with notable raises like one in May 2021 and another in June 2017, reflecting sustained focus on healthcare amid shifting market dynamics.[3]
Aisling Capital rides the biotech innovation wave, capitalizing on advances in therapeutics like those from portfolio companies (e.g., Biomea Fusion, Syndax) amid rising demand for novel treatments in oncology and rare diseases.[2] Timing aligns with post-2020 funding recovery in life sciences, where growth-stage investments bridge venture-to-public gaps, fueled by market forces like aging populations, AI-driven drug discovery, and regulatory tailwinds for breakthroughs.[1][3] The firm influences the ecosystem by enabling scale-ups—evident in holdings' public market presence—fostering a pipeline from startups to market leaders and amplifying NYC's biotech hub status.[2][3]
Aisling's concentrated, long-hold strategy positions it for outsized returns in high-conviction biotech bets, with portfolio growth signaling momentum into 2026.[2] Trends like precision medicine and mRNA expansions will shape its path, potentially driving new fundraises beyond the recent $280 million vehicle.[3] Influence may evolve through deeper public market plays or expanded debt strategies, solidifying its role as a healthcare ecosystem anchor—much like its inception-era focus on life sciences innovation that built today's resilient portfolio.[1][2]
